These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30381644)

  • 1. [Analysis of Risk Factors for Side Effects and the Establishment of Supportive Therapy during Cancer Chemotherapy].
    Sakurada T
    Yakugaku Zasshi; 2018; 138(11):1363-1370. PubMed ID: 30381644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer.
    Sakurada T; Kakiuchi S; Tajima S; Horinouchi Y; Okada N; Nishisako H; Nakamura T; Teraoka K; Kawazoe K; Yanagawa H; Nishioka Y; Minakuchi K; Ishizawa K
    Ann Pharmacother; 2015 Apr; 49(4):398-404. PubMed ID: 25565405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.
    Sakurada T; Kakiuchi S; Tajima S; Horinouchi Y; Konaka K; Okada N; Nishisako H; Nakamura T; Teraoka K; Kawazoe K; Yanagawa H; Nishioka Y; Ishizawa K
    Biol Pharm Bull; 2015; 38(11):1752-6. PubMed ID: 26521826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.
    Elsoueidi R; Lander MJ; Richa EM; Adane ED
    J Oncol Pharm Pract; 2016 Apr; 22(2):271-4. PubMed ID: 25908647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.
    Miyahara T; Sueoka-Aragane N; Iwanaga K; Ureshino N; Komiya K; Nakamura T; Nakashima C; Abe T; Matsunaga H; Kimura S
    Med Oncol; 2017 Nov; 34(12):195. PubMed ID: 29124473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
    Sakurada T; Nokihara H; Koga T; Zamami Y; Goda M; Yagi K; Hamano H; Aizawa F; Ogino H; Sato S; Kirino Y; Goto H; Nishioka Y; Ishizawa K
    Oncologist; 2022 Jul; 27(7):e554-e560. PubMed ID: 35325241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced Interstitial Lung Disease Has the Same Degree of Risk for Mortality as Old Age in Patients With Lung Cancer.
    Iwashita K; Mizuno T; Kumazawa S; Imaizumi K; Yamada S
    Anticancer Res; 2021 Mar; 41(3):1707-1711. PubMed ID: 33788769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world.
    Kaku S; Horinouchi H; Watanabe H; Yonemori K; Okusaka T; Boku N; Yamazaki N; Kawai A; Ohe Y; Kusumoto M
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1737-1746. PubMed ID: 35129672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of cutaneous reactions with pemetrexed: Comparison of patients who received three days of oral dexamethasone twice daily to patients who did not.
    Clark SK; Anselmo LM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1645-1650. PubMed ID: 30319062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
    Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
    Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
    Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.
    Terbuch A; Tiu C; Candilejo IM; Scaranti M; Curcean A; Bar D; Estevez Timon M; Ameratunga M; Ang JE; Ratoff J; Minchom AR; Banerji U; de Bono JS; Tunariu N; Lopez JS
    Clin Cancer Res; 2020 Sep; 26(18):4805-4813. PubMed ID: 32332017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of Patients With Interstitial Lung Disease Induced by Different Pharmacological Types of Anticancer Drugs.
    Iwashita K; Mizuno T; Kumazawa S; Imaizumi K; Yamada S
    Anticancer Res; 2021 May; 41(5):2563-2568. PubMed ID: 33952484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
    Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
    Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between two premedication regimens of dexamethasone before a pemetrexed-based chemotherapy: A single-center experience study.
    Groleau A; Côté J
    J Oncol Pharm Pract; 2020 Apr; 26(3):612-618. PubMed ID: 31370748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.